MONICA HALLQUIST: Open Payments
NPI 1962051086 · FESTUS, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$351 in 16 payments from 10 companies in 2025. Trend: 2023 $840 · 2024 $327 · 2025 $351
Food & beverage: $351
| Company | Payments | Amount |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 3 | $102 |
| ABBVIE INC. | 3 | $54 |
| Aimmune Therapeutics, Inc. | 2 | $47 |
| PFIZER INC. | 2 | $30 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $24 |
| QOL Medical, LLC | 1 | $21 |
| Gilead Sciences, Inc. | 1 | $21 |
| Phathom Pharmaceuticals, Inc. | 1 | $19 |
| Organon LLC | 1 | $17 |
| Lilly USA, LLC | 1 | $16 |
Products named: DUPIXENT, LINZESS, XIFAXAN, ZENPEP, VOWST, Sucraid, VOQUEZNA, RENFLEXIS.
Industry payments across MO — which companies pay providers there.
